These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 15136215

  • 1. Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.
    Kern W, Voskova D, Schoch C, Schnittger S, Hiddemann W, Haferlach T.
    Haematologica; 2004 May; 89(5):528-40. PubMed ID: 15136215
    [Abstract] [Full Text] [Related]

  • 2. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A, German AML Cooperative Group.
    J Clin Oncol; 2003 Dec 15; 21(24):4496-504. PubMed ID: 14673036
    [Abstract] [Full Text] [Related]

  • 3. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.
    Kern W, Danhauser-Riedl S, Ratei R, Schnittger S, Schoch C, Kolb HJ, Ludwig WD, Hiddemann W, Haferlach T.
    Haematologica; 2003 Jun 15; 88(6):646-53. PubMed ID: 12801840
    [Abstract] [Full Text] [Related]

  • 4. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
    Oriol A, Ribera JM, Esteve J, Guàrdia R, Brunet S, Bueno J, Pedro C, Llorente A, Tormo M, Besalduch J, Sánchez JM, Batlle M, Vivancos P, Carreras E, Vilà JM, Julià A, Sierra J, Montserrat E, Feliu E, CETLAM AML-99.
    Haematologica; 2004 Jul 15; 89(7):791-800. PubMed ID: 15257930
    [Abstract] [Full Text] [Related]

  • 5. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
    Gupta V, Chun K, Yi QL, Minden M, Schuh A, Wells R, Brandwein J.
    Cancer; 2005 May 15; 103(10):2082-90. PubMed ID: 15830348
    [Abstract] [Full Text] [Related]

  • 6. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
    Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H.
    Cancer; 2005 Aug 01; 104(3):547-54. PubMed ID: 15973664
    [Abstract] [Full Text] [Related]

  • 7. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
    MRD-AML-BFM Study GroupDepartment of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany. langebrake.claudia@mh-hannover.de, Langebrake C, Creutzig U, Dworzak M, Hrusak O, Mejstrikova E, Griesinger F, Zimmermann M, Reinhardt D.
    J Clin Oncol; 2006 Aug 01; 24(22):3686-92. PubMed ID: 16877738
    [Abstract] [Full Text] [Related]

  • 8. The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors.
    Weisser M, Haferlach C, Hiddemann W, Schnittger S.
    Leukemia; 2007 Jun 01; 21(6):1177-82. PubMed ID: 17377588
    [Abstract] [Full Text] [Related]

  • 9. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N, Thomas V, Abrahams L, du Toit C, McDonald A.
    Am J Hematol; 2004 Aug 01; 76(4):319-29. PubMed ID: 15282663
    [Abstract] [Full Text] [Related]

  • 10. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.
    Ann Hematol; 2004 Aug 01; 83(8):498-503. PubMed ID: 15156346
    [Abstract] [Full Text] [Related]

  • 11. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.
    Schlenk RF, Benner A, Krauter J, Büchner T, Sauerland C, Ehninger G, Schaich M, Mohr B, Niederwieser D, Krahl R, Pasold R, Döhner K, Ganser A, Döhner H, Heil G.
    J Clin Oncol; 2004 Sep 15; 22(18):3741-50. PubMed ID: 15289486
    [Abstract] [Full Text] [Related]

  • 12. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
    Al-Mawali A, Gillis D, Lewis I.
    Cytometry B Clin Cytom; 2009 Mar 15; 76(2):91-101. PubMed ID: 18727068
    [Abstract] [Full Text] [Related]

  • 13. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
    Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD.
    J Clin Oncol; 2005 Aug 20; 23(24):5705-17. PubMed ID: 16110030
    [Abstract] [Full Text] [Related]

  • 14. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D, Tabuchi K, Kinoshita A, Hanada R, Kigasawa H, Tsukimoto I, Tsuchida M, Tokyo Children's Cancer Study Group.
    Pediatr Blood Cancer; 2007 Aug 20; 49(2):127-32. PubMed ID: 16807916
    [Abstract] [Full Text] [Related]

  • 15. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
    Liu J, Mi Y, Fu M, Yu W, Wang Y, Lin D, Bian S, Wang J.
    Am J Hematol; 2009 Jul 20; 84(7):422-7. PubMed ID: 19484734
    [Abstract] [Full Text] [Related]

  • 16. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
    Wahlin A, Billström R, Björ O, Ahlgren T, Hedenus M, Höglund M, Lindmark A, Markevärn B, Nilsson B, Sallerfors B, Brune M.
    Eur J Haematol; 2009 Aug 20; 83(2):99-107. PubMed ID: 19385987
    [Abstract] [Full Text] [Related]

  • 17. [Prognostic value of early treatment response in children with acute myeloid leukemia].
    Tie LJ, Gu LJ, Song DL, Xue HL, Tang JY, Dong L, Pan C, Chen J, Ye H, Chen J, Wang YP, Zou JY.
    Zhonghua Yi Xue Za Zhi; 2006 Jul 11; 86(26):1837-40. PubMed ID: 17054861
    [Abstract] [Full Text] [Related]

  • 18. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
    Maurillo L, Buccisano F, Del Principe MI, Del Poeta G, Spagnoli A, Panetta P, Ammatuna E, Neri B, Ottaviani L, Sarlo C, Venditti D, Quaresima M, Cerretti R, Rizzo M, de Fabritiis P, Lo Coco F, Arcese W, Amadori S, Venditti A.
    J Clin Oncol; 2008 Oct 20; 26(30):4944-51. PubMed ID: 18606980
    [Abstract] [Full Text] [Related]

  • 19. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
    Farag SS, Ruppert AS, Mrózek K, Mayer RJ, Stone RM, Carroll AJ, Powell BL, Moore JO, Pettenati MJ, Koduru PR, Stamberg J, Baer MR, Block AW, Vardiman JW, Kolitz JE, Schiffer CA, Larson RA, Bloomfield CD.
    J Clin Oncol; 2005 Jan 20; 23(3):482-93. PubMed ID: 15534356
    [Abstract] [Full Text] [Related]

  • 20. Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
    Thomas X, Elhamri M, Chelghoum Y, Reman O, Arnaud P, Raffoux E, Le QH, Tavernier E, Dombret H, Michallet M.
    Ann Hematol; 2005 Jun 20; 84(6):376-82. PubMed ID: 15782343
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.